These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 4855463

  • 21. Evaluation of the clinical inequivalency of drug products of varying bioavailability.
    Barr WH, Adir J.
    Ann Clin Res; 1974; 6(0):suppl 11:48-56. PubMed ID: 4605465
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Pharmacokinetic studies on phenylbutazone in children.
    Gladtke E.
    Farmaco Sci; 1968 Oct; 23(10):897-906. PubMed ID: 5712791
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Bioavailability of methaqualone.
    Smyth RD, Lee JK, Polk A, Chemburkar PB, Savacool AM.
    J Clin Pharmacol; 1973 Oct; 13(10):391-400. PubMed ID: 4490663
    [No Abstract] [Full Text] [Related]

  • 27. The physiologic availability of phenylbutazone tablets marketed in India.
    Manek SP, Tipnis HP, Kulkarni RD.
    Int J Clin Pharmacol Ther Toxicol; 1981 Apr; 19(4):163-7. PubMed ID: 7263103
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. NSAID-plasma concentration monitoring--optimizing treatment of R.A.
    McGill PE.
    Agents Actions Suppl; 1985 Apr; 17():157-61. PubMed ID: 3867275
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Inhibition of phenylbutazone elimination by its metabolite oxyphenbutazone.
    Jähnchen E, Levy G.
    Proc Soc Exp Biol Med; 1972 Dec; 141(3):963-5. PubMed ID: 4645785
    [No Abstract] [Full Text] [Related]

  • 32. Effect of lead exposure on plasma phenylbutazone levels in rats.
    Basu N, Kulsreshtha T.
    Indian J Physiol Pharmacol; 1994 Jan; 38(1):61-2. PubMed ID: 8132249
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Protein binding of indomethacin: binding of indomethacin to human plasma albumin and its displacement from binding by ibuprofen, phenylbutazone and salicylate, in vitro.
    Mason RW, McQueen EG.
    Pharmacology; 1974 Jan; 12(1):12-9. PubMed ID: 4419599
    [No Abstract] [Full Text] [Related]

  • 35. Sustained-release tablets of indomethacin-loaded microcapsules: preparation, in vitro and in vivo characterization.
    Lu B, Wen R, Yang H, He Y.
    Int J Pharm; 2007 Mar 21; 333(1-2):87-94. PubMed ID: 17081709
    [Abstract] [Full Text] [Related]

  • 36. Relationships between the concentrations of prostaglandins and the nonsteroidal antiinflammatory drugs indomethacin, diclofenac, and ibuprofen.
    Giagoudakis G, Markantonis SL.
    Pharmacotherapy; 2005 Jan 21; 25(1):18-25. PubMed ID: 15767216
    [Abstract] [Full Text] [Related]

  • 37. Choice of subjects for in vivo studies in generic equivalency.
    Carr EA.
    Ann Clin Res; 1974 Jan 21; 6(0):suppl 11:57-66. PubMed ID: 4855466
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Therapeutic non-equivalence.
    Br Med J; 1972 Sep 09; 3(5827):599-600. PubMed ID: 5071688
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.